Strike Pharma

What Strike Pharma does

Strike Pharma AB is a privately held Swedish biotech founded in 2020 in Uppsala, developing in vivo cell therapies for autoimmune disease and cancer. The company is built around a single proprietary technology platform called ADAC (Adaptable Drug Affinity Conjugate), which exploits a high-affinity, low-picomolar, induced-fit interaction between a synthetic peptide tag (pTag, only nine amino acids and lacking secondary structure) and a single-chain variable fragment (scFv) antibody. By attaching the pTag to lipid nanoparticle (LNP) payloads and the scFv to a targeting antibody (typically a bivalent bispecific), ADAC enables post-storage modular conjugation, addressing CMC, manufacturing, and long-term storage challenges that constrain conventional antibody-drug and antibody-LNP approaches.

The ADAC platform powers a preclinical pipeline of in vivo CAR-M and in vivo CAR-T candidates. The lead in vivo CAR-M program targets autoreactive T cells for T-cell dependent autoimmune disease such as rheumatoid arthritis and spondyloarthritis, while a second in vivo CAR-M program is directed at tumor-infiltrating regulatory T cells to augment solid tumor immunotherapy. A third program, StAb19, is a B-cell targeting in vivo CAR-T co-developed with AbClon Inc. under a February 2026 Eurostars grant, intended for B-cell dependent autoimmune diseases (including SLE) and B-cell malignancies. A separate candidate, STRIKE-2001, is a bispecific anti-CD40 agonistic antibody that uses ADAC for modular synthetic long peptide vaccine delivery. Internal performance claims include more than 10-fold improvement in monocyte uptake and expression of CAR mRNA versus naked LNPs.

Strike Pharma is pre-revenue and pre-clinical, with no commercial products, no publicly disclosed pricing, and no named end-customer logos. The company has raised approximately $6 million across a 2021 SEK 10 million private placement (Almi Invest) and a 2022 round (~$4.82 million led by EIR Ventures with Flerie Invest), and benefits from a February 2026 Eurostars grant. Future revenue is expected to come from licensing deals, strategic co-development partnerships, and grants rather than direct product sales. The team of roughly 12–13 includes a commercially experienced CEO (Per Norlén, appointed February 2025) and is anchored scientifically by co-founder and CSO Sara Mangsbo (Uppsala University) and co-founder Johan Rockberg (KTH), with research collaborations spanning Uppsala University, KTH, SciLifeLab DDD, and Karolinska Institutet.

Name

Strike Pharma

Legal name

Strike Pharma AB

Website

https://strikepharma.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Strike Pharma is a Swedish preclinical biotech developing the proprietary ADAC platform for targeted lipid nanoparticle delivery, enabling in vivo CAR-M and CAR-T therapies for autoimmune disease and cancer through future pharma licensing and co-development partnerships.

Ownership category

akta.pro rank

Product category

Preclinical Biotech (In Vivo Cell Therapy)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Fusion Proteins & Fc-Engineered Biologics (HLAAAAAD), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• In vivo CAR-T therapy
• In vivo CAR-M therapy
• Targeted LNP delivery
• Antibody-drug conjugates
• Cancer immunotherapy

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Private placement capital raise: Pre-revenue biotech company that raised SEK 10 million ($1.2 million) in a 2021 private placement from investors including Almi Invest. Additional investors include Eir Ventures, Flerie Invest, AB Ility, and Monesi Förvaltnings AB. Future revenue is expected to come from licensing deals, strategic partnerships, and potential grants (e.g., Eurostars grant from Feb 2026).

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Strike Pharma develops a proprietary Adaptable Drug Affinity Conjugate (ADAC) technology platform that enables targeted delivery of lipid nanoparticles (LNPs) to specific immune cells via a high-affinity interaction between a 9-amino-acid peptide tag (pTag) and a single-chain variable fragment (scFv) antibody. The platform underpins a preclinical pipeline of in vivo CAR-M and in vivo CAR-T therapies intended for autoimmune disease and cancer immunotherapy, including the lead in vivo CAR-M program for T-cell dependent autoimmune disease, a second in vivo CAR-M program for solid tumor immunotherapy, the StAb19 B-cell targeting in vivo CAR-T candidate co-developed with AbClon Inc., and the STRIKE-2001 bispecific anti-CD40 antibody vaccine candidate.

Product overview

Strike Pharma is a Swedish biotech company whose offering centers on a single core technology platform — the proprietary ADAC (Adaptable Drug Affinity Conjugate) platform — that powers a portfolio of preclinical in vivo cell therapy programs. The ADAC platform enables targeted delivery of lipid nanoparticles (LNPs) through a high-affinity pTag/scFv interaction and underpins the company's in vivo CAR-M programs (lead program for T-cell dependent autoimmune disease such as rheumatoid arthritis and spondyloarthritis, plus a second program targeting tumor-infiltrating regulatory T cells in solid tumors). It also underpins StAb19, a B-cell targeting in vivo CAR-T candidate developed in collaboration with AbClon Inc. under a Eurostars grant, and STRIKE-2001, a bispecific anti-CD40 antibody vaccine candidate that uses ADAC for modular peptide cargo delivery to antigen-presenting cells. Together, the ADAC platform and these named in vivo CAR-M, StAb19 in vivo CAR-T, and STRIKE-2001 programs form Strike Pharma's unified research-stage product portfolio for autoimmune disease and cancer immunotherapy.

Differentiator

Problem solved

Functional benefit

Brands

• StAb19: B-cell targeting in vivo CAR-T candidate co-developed with AbClon Inc. under a Eurostars grant; based on a CD3-targeting antibody and a CD19 CAR with optimized off-rate.
• ADAC

Products and services

• ADAC Technology Platform (Adaptable Drug Affinity Conjugate) A proprietary technology platform that enables targeted delivery of lipid nanoparticles (LNPs) via a high-affinity interaction between a proprietary synthetic peptide tag (pTag, 9 amino acids) and a single-chain variable fragment (scFv) antibody fragment. The pTag is fused to payloads (peptides, antisense oligonucleotides, small molecules, LNPs), while the scFv is attached to a targeting antibody, allowing modular conjugation by simple mixing after storage. The platform powers Strike Pharma's pipeline of in vivo CAR-M and in vivo CAR-T candidates and underpins the company's co-development programs.
• In vivo CAR-M Programs First-in-class in vivo CAR-M therapies based on targeted LNPs that deliver CAR mRNA to monocytes, which then express the CAR and differentiate into macrophages that infiltrate inflamed tissues. The lead program targets autoreactive T cells for T-cell dependent autoimmune diseases (including rheumatoid arthritis and spondyloarthritis); a second program targets tumor-infiltrating regulatory T cells to augment cancer immunotherapy in solid tumors.
• StAb19 (in vivo CAR-T) B-cell targeting in vivo CAR-T candidate developed in collaboration with AbClon Inc. under a Eurostars grant. Built on an LNP carrying mRNA for an anti-CD19 CAR and a bispecific antibody that binds the LNP and CD3, reprogramming T cells in vivo to seek and kill CD19-expressing B cells. Intended for B-cell dependent autoimmune disease (including SLE) and B-cell malignancies.
• STRIKE-2001 (bispecific anti-CD40 antibody) A bivalent anti-CD40 agonistic antibody in IgG2 bispecific format equipped with a peptide-binding scFv (binding a short pTag in the low nM range) that enables modular, affinity-based attachment of tumor-associated antigen peptide cargo via the ADAC technology. Designed to deliver peptide antigens to antigen-presenting cells while retaining agonistic CD40 activity for combined T-cell priming and immune activation.

Quantifiable outcome

• More than 10-fold increase in monocyte uptake and expression of CAR mRNA vs naked LNPs
• +2 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered flagship, core and minor.

• AbClon Inc.flagshipStrategic or Co-development Partner · 1 February 2026Co-development collaboration under a Eurostars grant for the StAb19 in vivo CAR-T program — a B-cell targeting in vivo CAR-T combining CD3-targeting antibody and a novel CD19 CAR binding to a unique epitope, optimized for fast off-rate. Strike Pharma announced receipt of the Eurostars grant in February 2026 for this project.
• Uppsala University (Department of Pharmaceutical Sciences)coreStrategic or Co-development PartnerFounding research collaboration. Strike Pharma was founded in 2020 on the scientific discoveries of Professor Sara Mangsbo and her research team at the Department of Pharmaceutical Sciences, Uppsala University. A grant for technology validation was awarded by UU Innovation, Uppsala University's commercial potential assessment organization. CSO Sara Mangsbo remains Associate Professor at Uppsala University.
• KTH Royal Institute of Technology (Kungliga Tekniska Högskolan)coreStrategic or Co-development PartnerCo-founder Johan Rockberg, Professor in Antibody Technology and Directed Evolution at KTH, is a scientific co-founder. KTH research groups (Johan Rockberg, Helena Persson) co-author Strike Pharma scientific publications and posters on the ADAC technology platform.
• SciLifeLab Drug Discovery and Development (DDD) PlatformcoreStrategic or Co-development PartnerSciLifeLab's Drug Discovery and Development Platform was a co-developer of the ADAC technology alongside Uppsala University and KTH. SciLifeLab is a Swedish national resource for molecular biosciences. Scientific posters list SciLifeLab DDD platform as a contributing affiliation.
• Karolinska University / Karolinska InstitutetminorStrategic or Co-development PartnerResearch collaboration; Helena Persson and colleagues at Karolinska co-author Strike Pharma's scientific publications and posters on ADAC technology and bispecific anti-CD40 antibodies.
• SmiLe Venture Hub (Medicon Village, Lund)minorOthersStrike Pharma's operating/mailing address is c/o SmiLe Venture Hub at Scheeletorget 1, Medicon Village, 223 81 Lund, Sweden. SmiLe is a Swedish life science incubator.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Allogene Therapeutics: Clinical-stage leader in allogeneic (off-the-shelf) CAR-T therapies. A broader incumbent in the off-the-shelf cell therapy space, providing the closest commercial-stage benchmark for the value proposition of Strike's in vivo CAR-T programs.

Direct peers

• Capstan Therapeutics: US-based preclinical-stage biotech developing in vivo CAR-T therapies using LNP-delivered mRNA. Direct competitor to Strike Pharma's in vivo CAR-T (StAb19) and CAR-M programs, with a similar off-the-shelf, redoseable value proposition.
• Interius BioTherapeutics: Preclinical-to-clinical-stage biotech developing in vivo CAR-T candidates using targeted lentiviral vectors. Directly comparable as a competing approach to off-the-shelf, in-body CAR-T generation that Strike's ADAC-LNP platform is also pursuing.
• Umoja Biopharma: Clinical-stage in vivo CAR-T platform company developing off-the-shelf cell therapies using viral and LNP delivery. Closest direct competitor in the in vivo CAR-T space, advancing multiple programs toward the clinic.
• Orna Therapeutics: Clinical-stage biotech developing in vivo CAR-T and other cell therapies using engineered circular RNA delivered via LNP. Direct competitor in the in vivo cell reprogramming space with overlapping autoimmune and oncology indications.

Emerging players

• Kyverna Therapeutics: Clinical-stage biotech developing autologous and next-generation CAR-T therapies for autoimmune disease including lupus and multiple sclerosis. Comparable in B-cell-driven autoimmune indication strategy, providing pharma-partner benchmarks relevant to Strike's StAb19 program.
• Cabaletta Bio: Clinical-stage biotech developing autologous CAR-T candidates (e.g., CABA-201) for B-cell driven autoimmune diseases like SLE. Overlapping disease focus with Strike's StAb19 program, though Cabaletta's approach is ex vivo rather than in vivo.
• EsoBiotec: Belgium-based biotech developing in vivo CAR-T (its BDD platform) using targeted lentiviral delivery to immune cells. Comparable in vivo cell-therapy mechanism, though delivery vehicle differs from Strike's LNP-based ADAC approach.

Others

• Cibus Bio (Moderna-partnered LNP companies): Acuitas Therapeutics and similar LNP technology providers supply the lipid nanoparticle delivery technology that Strike's ADAC platform depends on. Indirect comparability as adjacent infrastructure/enabling technology for in vivo cell therapy approaches.
• AbClon Inc. South Korean antibody engineering company and Strike Pharma's co-development partner on the StAb19 in vivo CAR-T program. Comparable antibody-engineering capabilities (CD19 CAR, novel epitopes) and an explicit strategic partner rather than direct competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/strike-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Strike Pharma